Health Topics — Metabolic & Cognitive
When Inflammation Is Behind Your Metabolic Problems
For the person whose blood sugar, energy, or weight is trending in the wrong direction despite doing the right things — what chronic low-grade inflammation does to insulin signalling, and why it often goes unaddressed.
You are eating reasonably well. You are moving. You are doing what you were told to do. And yet your blood sugar is creeping up, your energy is unreliable, and your body is not responding the way it should to your efforts. Your doctor says to keep watching it.
What is often missing from this conversation is inflammation — not the acute inflammation of an injury or infection, but the low-grade chronic kind that produces no obvious symptoms and shows up only in bloodwork trends and in the gradual deterioration of systems that were working fine before.
Visceral fat is not passive storage
The first thing worth understanding is that fat — specifically the fat stored deep in the abdomen around the organs, called visceral fat — is not simply a passive energy reserve waiting to be used. It is metabolically active tissue. It produces hormones. It sends signals. And when there is too much of it, those signals are predominantly inflammatory.
Visceral fat tissue releases a continuous low-level stream of inflammatory molecules — including TNF-α and IL-6, two of the most studied inflammatory signals in metabolic research. These molecules circulate throughout the body and land on cells in the liver, muscle, and pancreas — the tissues responsible for managing blood glucose. When they arrive, they interfere directly with how those cells respond to insulin.
This is the mechanism that connects excess visceral fat to insulin resistance — not simply that fat stores energy, but that it actively signals the rest of the body in ways that disrupt glucose regulation. The more visceral fat, the louder the inflammatory signal, and the more resistant the target tissues become to insulin's instructions.
What insulin resistance actually means in daily life
Insulin resistance is not a binary state — it develops gradually, and most people live with a significant degree of it before any formal diagnosis. The experience is familiar even when the mechanism is not: energy that crashes after meals rather than sustaining. Hunger that returns too quickly. Difficulty losing weight despite reasonable caloric intake. Mental fog in the afternoon. Craving for carbohydrates that feels almost physical.
These are not character flaws or failures of willpower. They are downstream consequences of cells that have become less responsive to insulin's signals — cells that need more and more of it to do the same job, and that are doing that job less efficiently than they once did. The pancreas compensates by producing more insulin, blood insulin levels rise, and the whole system runs hotter and less efficiently than it was designed to.
What makes the inflammatory pathway particularly frustrating is that it tends to be self-reinforcing. Visceral fat produces inflammatory signals that cause insulin resistance. Insulin resistance makes it harder to burn visceral fat. More visceral fat produces more inflammatory signals. The cycle tightens gradually, often for years, before it becomes visible in clinical markers.
Where stress enters the picture
Chronic stress compounds this process through a separate but connected pathway. Cortisol — the primary stress hormone — directly suppresses insulin sensitivity in muscle and fat tissue. It also promotes the accumulation of visceral fat specifically, because visceral fat has more cortisol receptors than subcutaneous fat and responds to chronic cortisol exposure by growing. The result is that a person under sustained chronic stress is simultaneously accumulating more inflammatory visceral fat and having their insulin sensitivity suppressed by the cortisol itself.
This is why the metabolic consequences of chronic stress can look identical to the metabolic consequences of a poor diet — and why addressing stress load is often as important as addressing food choices in the broader metabolic picture. Both pathways converge on the same insulin signalling biology.
Where the endocannabinoid system connects
The endocannabinoid system is present throughout the metabolic tissues involved in this process — in visceral fat, in the liver, in muscle, in the pancreas. Its role in metabolic regulation has been one of the more active areas of preclinical research over the past two decades, driven partly by the dramatic metabolic effects seen when the CB1 receptor was blocked pharmacologically in obesity research.
CB2 receptors in adipose tissue and immune cells have been associated in preclinical models with reduced inflammatory signalling — including the TNF-α and IL-6 production from visceral fat described above. The PPAR-γ receptor — a protein that regulates insulin sensitivity genes in fat and liver tissue — is a documented target of CBG. PPAR-γ activation reduces the inflammatory gene expression that contributes to insulin resistance, and is the same mechanism targeted by a class of pharmaceutical diabetes medications.
Whether these preclinical mechanisms translate to meaningful benefit in humans with metabolic inflammation is not yet established by clinical trial evidence. The research archive article on this topic covers the mechanisms in full detail, with honest accounting of where the evidence is strong and where it runs out. What the mechanisms suggest is a coherent biological rationale — not a treatment claim.
What this means practically
If your metabolic markers are trending in the wrong direction, the inflammatory pathway described here is worth discussing with your doctor — particularly if you carry significant visceral fat or have been under sustained chronic stress. Asking about inflammatory markers (CRP, IL-6 where available) alongside standard glucose and insulin measures gives a more complete picture of what may be driving the trend.
Addressing visceral fat accumulation, chronic stress load, sleep quality, and dietary inflammatory burden are the best-established interventions for metabolic inflammation. Cannabinoid preparations sit in the research landscape as a potential supporting element — not a replacement for those foundational interventions, and not a substitute for medical management of diagnosed metabolic conditions.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.